Yeah? Clinical and medical inexperience? How about
Post# of 148126
If anything I'm showing my age... It's a DSMB, to anyone and everyone in both the industry and regulatory bodies, and most of the investing world (that's been out of diapers since the Carter administration, anyway). My 'biotech experience' was with one of the bloated turds attempting to feign efficacy and relevance for their 'vaccine candidate'... I was with them for longer than you've come out of your closet, no doubt, and left when their response to their aging pipeline was to double down on marketing and patenting dubious combo therapies.
That's just the 'biotech experience'. In the investing world, men whose morning bowel movements have more impact on the US equities and bond markets on any given day have more significance than you, cumulatively, could hope to have in your lifetime... They know exactly who I am.
You are the neophyte that doesn't understand the significance of *suggesting* the addition of an extended endpoint of an *interim analysis* to seal the deal on an efficacy stop. No thesaurus will save you, there.